Firebrick Pharma Ltd FRE
Trading Information
- Previous Close Price
- A$0.03
- Day Range
- A$0.03–0.03
- 52-Week Range
- A$0.02–0.07
- Bid/Ask
- A$0.03 / A$0.03
- Shares Outstanding
- 308.11M
- Market Cap
- A$9.24M
- Volume/Avg
- 2,243 / 132,070
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 67.15
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Firebrick Pharma Ltd is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine AE brand, with its anchor product being Nasodine AE Nasal Spray, which is in the commercialization phase and launched in several markets. The company operates in one business segment, namely the development and commercialization of nasal sprays. Geographically it operates in Asia which generates the maximum revenue, followed by North America, Europe and others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
Valuation
Metric | FRE |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.75 |
Price/Sales | 67.15 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | FRE |
|---|---|
Quick Ratio | 2.84 |
Current Ratio | 3.85 |
Interest Coverage | — |
Quick Ratio
FRE
Profitability
Metric | FRE |
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
FRE
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|<!vL@^ND | LOCK|VM> | $1T | |||
| Johnson & Johnson JNJ | LOCK|KYXyd> | LOCK|##N | $680B | |||
| AbbVie Inc ABBV | LOCK|wx#!XS | LOCK|l% | $521B | |||
| Roche Holding AG ADR RHHBY | LOCK|tn!j&L$ | LOCK|!# | $389B | |||
| Merck & Co Inc MRK | LOCK|y%Dnxq% | LOCK|VvK | $356B | |||
| Novartis AG ADR NVS | LOCK|<c$@D&x | LOCK|<% | $306B | |||
| AstraZeneca PLC AZN | LOCK|T$mvFbk | LOCK|JW | $288B | |||
| Amgen Inc AMGN | LOCK|wZ><B&M | LOCK|BQ | $250B | |||
| Gilead Sciences Inc GILD | LOCK|>Z#ZP?T | LOCK|n> | $208B | |||
| Novo Nordisk AS ADR NVO | LOCK|JXYn@&< | LOCK|Kb! | $185B |